Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

PD‐L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade

Open access
Peng, Qi, Qiu, Xiangyan, Zhang, Zihan, Zhang, Silin, Zhang, Yuanyuan, Liang, Yong, Guo, Jingya, Peng, Hua, Chen, Mingyi, Fu, Yang-Xin, Tang, Haidong · 2020 · Nature Communications

Abstract

Immune checkpoint blockade therapies have shown clinical promise in a variety of cancers, but how tumor-infiltrating T cells are activated remains unclear. In this study, we explore the functions of PD-L1 on dendritic cells (DCs), which highly express PD-L1. We observe that PD-L1 on DC plays a critical role in limiting T cell responses. Type 1 conventional DCs are essential for PD-L1 blockade and they upregulate PD-L1 upon antigen uptake. Upregulation of PD-L1 on DC is mediated by type II interferon. While DCs are the major antigen presenting cells for cross-presenting tumor antigens to T cells, subsequent PD-L1 upregulation protects them from killing by cytotoxic T lymphocytes, yet dampens the antitumor responses. Blocking PD-L1 in established tumors promotes re-activation of tumor-infiltrating T cells for tumor control. Our study identifies a critical and dynamic role of PD-L1 on DC, which needs to be harnessed for better invigoration of antitumor immune responses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-020-18570-x

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 PD-L1 on DCs is important for T cell priming during antitumor immune responses. a WT B6 mice (n = 8) were inoculated with 5 × 105 MC38 cells and analyzed by flow cytometry on day 14 after inoculation. PD-L1 expression levels on CD8+ T (CD3+CD8+), CD4+ T (CD3+CD4+), B (CD19+), macrophage (CD11b+F4/80+), MDSC (CD11b+Gr-1+), DC (CD11c+MHC II+), and tumor (CD45−) cells were shown. FMO, fluorescence minus one; MFI, mean fluorescent intensities. b Knockout strategy. LoxP sites were inserted flanking exons 2 and 3. c PD-L1 expression on DCs and control cells (CD11c−MHC II+) were measured by flow cytometry in CD11c-cre;Pdl1fl/fl and control mice. d CD11c-cre;Pdl1fl/fl or control mice (n = 4) were inoculated with 5 × 105 MC38 cells. Tumor sizes were measured twice a week. e MC38 tumor tissues were collected from CD11c-cre;Pdl1fl/fl or control mice (n = 6 Cre-, 7 Cre+) on day 14 after inoculation. PD-L1 levels on tumor cells were measured by flow cytometry. f CD11c-cre;Pdl1fl/fl or control mice (n = 5) were inoculated with E.G7 cells. Percentages of OVA-specific CD8+ T cells in PBMC were stained by tetramer on day 12. *p = 0.0399. g CD11c-cre;Pdl1fl/fl or control mice (n = 5) were inoculated with MC38-SIY cells. DCs were isolated from dLNs on day 14 and incubated with purified 2C T cells with or without SIY peptide restimulation. Forty-eight hours later, IFN-γ production was measured by ELISPOT. n.d., not detected. *p = 0.0172. Data are shown as mean ± SEM (a, e, f, and g) or mean + SEM (d) and are representative of two (d, e, f, and g) or three (a and c) independent experiments. n.s., not significant; *p < 0.05 determined by unpaired two-tailed Student’s t test. Source data are provided as a Source Data file.
Fig. 1 PD-L1 on DCs is important for T cell priming during antitumor immune responses. a WT B6 mice (n = 8) were inoculated with 5 × 105 MC38 cells and analyzed by flow cytometry on day 14 after inoculation. PD-L1 expression levels on CD8+ T (CD3+CD8+), CD4+ T (CD3+CD4+), B (CD19+), macrophage (CD11b+F4/80+), MDSC (CD11b+Gr-1+), DC (CD11c+MHC II+), and tumor (CD45−) cells were shown. FMO, fluorescence minus one; MFI, mean fluorescent intensities. b Knockout strategy. LoxP sites were inserted flanking exons 2 and 3. c PD-L1 expression on DCs and control cells (CD11c−MHC II+) were measured by flow cytometry in CD11c-cre;Pdl1fl/fl and control mice. d CD11c-cre;Pdl1fl/fl or control mice (n = 4) were inoculated with 5 × 105 MC38 cells. Tumor sizes were measured twice a week. e MC38 tumor tissues were collected from CD11c-cre;Pdl1fl/fl or control mice (n = 6 Cre-, 7 Cre+) on day 14 after inoculation. PD-L1 levels on tumor cells were measured by flow cytometry. f CD11c-cre;Pdl1fl/fl or control mice (n = 5) were inoculated with E.G7 cells. Percentages of OVA-specific CD8+ T cells in PBMC were stained by tetramer on day 12. *p = 0.0399. g CD11c-cre;Pdl1fl/fl or control mice (n = 5) were inoculated with MC38-SIY cells. DCs were isolated from dLNs on day 14 and incubated with purified 2C T cells with or without SIY peptide restimulation. Forty-eight hours later, IFN-γ production was measured by ELISPOT. n.d., not detected. *p = 0.0172. Data are shown as mean ± SEM (a, e, f, and g) or mean + SEM (d) and are representative of two (d, e, f, and g) or three (a and c) independent experiments. n.s., not significant; *p < 0.05 determined by unpaired two-tailed Student’s t test. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 2 PD-L1 on DCs is essential for the response to PD-L1 blockade therapy. a MC38 tumors established in CD11c-cre;Pdl1fl/fl (n = 5) or control mice (n = 4 IgG, 5 anti-PD-L1) were treated with IgG or anti-PD-L1 on day 8 and 12. Tumor growth curves were shown. ***p = 0.0007. b WT (n = 4 IgG, 5 anti-PD-L1) or Batf3−/− mice (n = 3 IgG, 4 anti-PD-L1) were inoculated with 5 × 105 MC38 cells. Mice were treated with IgG or anti-PD-L1 on day 8 and 12. Tumor growth curves were shown. ***p < 0.0001. Data are shown as mean + SEM and are representative of two independent experiments. n.s., not significant; ***p < 0.001 determined by two-way ANOVA. Source data are provided as a Source Data file.
Fig. 2 PD-L1 on DCs is essential for the response to PD-L1 blockade therapy. a MC38 tumors established in CD11c-cre;Pdl1fl/fl (n = 5) or control mice (n = 4 IgG, 5 anti-PD-L1) were treated with IgG or anti-PD-L1 on day 8 and 12. Tumor growth curves were shown. ***p = 0.0007. b WT (n = 4 IgG, 5 anti-PD-L1) or Batf3−/− mice (n = 3 IgG, 4 anti-PD-L1) were inoculated with 5 × 105 MC38 cells. Mice were treated with IgG or anti-PD-L1 on day 8 and 12. Tumor growth curves were shown. ***p < 0.0001. Data are shown as mean + SEM and are representative of two independent experiments. n.s., not significant; ***p < 0.001 determined by two-way ANOVA. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 3 PD-L1 on DCs is upregulated by IFN-γ and T cells in tumor microenvironment. a, b In naïve or MC38 tumor-bearing WT mice, PD-L1 levels on cDC1 (CD11b−CD24+) and cDC2 (CD11b+CD24−) were measured by flow cytometry (n = 7, except naïve spleen n = 6). ***p < 0.0001; *p = 0.0106; **p = 0.0030. c BMDCs were generated by FLT3-L. PD-L1 levels were measured by flow cytometry (n = 3). **p = 0.0010. d BMDCs were treated with recombinant IFN-α or IFN-γ. PD-L1 levels were measured 24 h later (n = 3). ***p(IFN-α) < 0.0001; ***p(IFN-γ) < 0.0001. e Purified WT DCs were treated with IFN-α or IFN-γ. PD-L1 levels were measured 24 h later (n = 3 mock, 4 IFN-α, 4 IFN-γ). **p(cDC1:IFN-α) = 0.0022; **p(cDC1:IFN-γ) = 0.0015; ***p(cDC2:IFN-α) < 0.0001; ***p(cDC2:IFN-γ) < 0.0001. f C57BL/6 mice (n = 7, except anti-IFNAR1 n = 6) were inoculated with 5 × 105 MC38-EGFP cells. Mice were treated with IgG, anti-IFNAR1, anti-IFN-γ, or anti-CD8. PD-L1 levels on cDC1 and cDC2 in tumor tissues were measured by flow cytometry on day 14 after inoculation. *p = 0.0208; ***p = 0.0005. g Purified WT DCs and activated CD8+ T cells were cocultured with or without anti-IFN-γ for 24 h. PD-L1 levels on cDC1 and cDC2 were measured by flow cytometry (n = 4, except DC + T n = 3). *p = 0.0442; **p = 0.0013. Data are shown as mean ± SEM and are representative of two independent experiments a, c–e, and g or pool of two independent experiments (b and f). n.s., not significant; *p < 0.05; **p < 0.01; ***p < 0.001 determined by unpaired two-tailed Student’s t test. Source data are provided as a Source Data file.
Fig. 3 PD-L1 on DCs is upregulated by IFN-γ and T cells in tumor microenvironment. a, b In naïve or MC38 tumor-bearing WT mice, PD-L1 levels on cDC1 (CD11b−CD24+) and cDC2 (CD11b+CD24−) were measured by flow cytometry (n = 7, except naïve spleen n = 6). ***p < 0.0001; *p = 0.0106; **p = 0.0030. c BMDCs were generated by FLT3-L. PD-L1 levels were measured by flow cytometry (n = 3). **p = 0.0010. d BMDCs were treated with recombinant IFN-α or IFN-γ. PD-L1 levels were measured 24 h later (n = 3). ***p(IFN-α) < 0.0001; ***p(IFN-γ) < 0.0001. e Purified WT DCs were treated with IFN-α or IFN-γ. PD-L1 levels were measured 24 h later (n = 3 mock, 4 IFN-α, 4 IFN-γ). **p(cDC1:IFN-α) = 0.0022; **p(cDC1:IFN-γ) = 0.0015; ***p(cDC2:IFN-α) < 0.0001; ***p(cDC2:IFN-γ) < 0.0001. f C57BL/6 mice (n = 7, except anti-IFNAR1 n = 6) were inoculated with 5 × 105 MC38-EGFP cells. Mice were treated with IgG, anti-IFNAR1, anti-IFN-γ, or anti-CD8. PD-L1 levels on cDC1 and cDC2 in tumor tissues were measured by flow cytometry on day 14 after inoculation. *p = 0.0208; ***p = 0.0005. g Purified WT DCs and activated CD8+ T cells were cocultured with or without anti-IFN-γ for 24 h. PD-L1 levels on cDC1 and cDC2 were measured by flow cytometry (n = 4, except DC + T n = 3). *p = 0.0442; **p = 0.0013. Data are shown as mean ± SEM and are representative of two independent experiments a, c–e, and g or pool of two independent experiments (b and f). n.s., not significant; *p < 0.05; **p < 0.01; ***p < 0.001 determined by unpaired two-tailed Student’s t test. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 4 PD-L1 on cDC1s is upregulated during antigen presentation by IFN-γ. a WT B6 mice were inoculated with 5 × 105 MC38-EGFP cells. After tumor established, tumors and draining LNs (n = 8 mice) were isolated on day 14. EGFP+ cells on cDC1 and cDC2 were measured by flow cytometry. b PD-L1 levels on total and EGFP+ cDC1s in draining LN were shown. c PD-L1 levels on EGFP− and EGFP+ DCs in tumor tissues were shown (n = 6 mice). **p = 0.0035. d BMDCs were co-culture with MC38 or MC38-EGFP cells for 24 h. Percentages of EGFP+ cells were shown (n = 3). e PD-L1 levels on EGFP− and EGFP+ BMDCs were shown (n = 4 cells, except FMO n = 3). ***p = 0.0003. f, g WT B6 mice were inoculated with 5 × 105 MC38-EGFP cells. Mice were treated with IgG, anti-IFNAR1, anti-IFN-γ, or anti-CD8 to block each pathway. Tumor tissues were collected and analyzed on day 14. f Percentages of EGFP+ cDC1s (n = 7 mice) were shown. g PD-L1 levels on EGFP− and EGFP+ cDC1s (n = 3 mice) were measured by flow cytometry. *p = 0.0489. Data are shown as mean ± SEM and are representative of two independent experiments (b, c–e, and g) or pool of two independent experiments (a and f). n.s., not significant; *p < 0.05; **p < 0.01 determined by unpaired two-tailed Student’s t test. Source data are provided as a Source Data file.
Fig. 4 PD-L1 on cDC1s is upregulated during antigen presentation by IFN-γ. a WT B6 mice were inoculated with 5 × 105 MC38-EGFP cells. After tumor established, tumors and draining LNs (n = 8 mice) were isolated on day 14. EGFP+ cells on cDC1 and cDC2 were measured by flow cytometry. b PD-L1 levels on total and EGFP+ cDC1s in draining LN were shown. c PD-L1 levels on EGFP− and EGFP+ DCs in tumor tissues were shown (n = 6 mice). **p = 0.0035. d BMDCs were co-culture with MC38 or MC38-EGFP cells for 24 h. Percentages of EGFP+ cells were shown (n = 3). e PD-L1 levels on EGFP− and EGFP+ BMDCs were shown (n = 4 cells, except FMO n = 3). ***p = 0.0003. f, g WT B6 mice were inoculated with 5 × 105 MC38-EGFP cells. Mice were treated with IgG, anti-IFNAR1, anti-IFN-γ, or anti-CD8 to block each pathway. Tumor tissues were collected and analyzed on day 14. f Percentages of EGFP+ cDC1s (n = 7 mice) were shown. g PD-L1 levels on EGFP− and EGFP+ cDC1s (n = 3 mice) were measured by flow cytometry. *p = 0.0489. Data are shown as mean ± SEM and are representative of two independent experiments (b, c–e, and g) or pool of two independent experiments (a and f). n.s., not significant; *p < 0.05; **p < 0.01 determined by unpaired two-tailed Student’s t test. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 5 PD-L1 blockade reactivates T cells in tumor microenvironment for tumor control. a, b C57BL/6 mice (n = 6, except day 14 FTY720 + anti-PD-L1 n = 5) were inoculated with 2.5 × 105 MC38-OVA cells and treated with (a) 200 μg IgG or anti-PD-L1 on days 8 and 12, or (b) 250 μg IgG or anti-PD-L1 on days 14 and 18. Mice were also treated with control or FTY720 the same day as antibody treatment. Tumor growth curves were shown. ***p(8: IgG vs anti-PD-L1) < 0.0001; ***p(8: anti-PD-L1 vs FTY720+anti-PD-L1) < 0.0001; ***p(14: IgG vs anti-PD-L1) < 0.0001. c Mice (n = 4, except day 14 FTY720 + anti-PD-L1 n = 3) were treated as in 5a and 5b. IFN-γ+ CD8 T cells in tumor tissues were measured by flow cytometry on day 13 (for day 8 treatment group) or on day 19 (for day 14 treatment group). *p(8: IgG vs anti-PD-L1) = 0.0462; *p(14: IgG vs anti-PD-L1) = 0.0443; *p(14: FTY720+IgG vs FTY720+anti-PD-L1) = 0.0119; *p(8: anti-PD-L1 vs FTY720+anti-PD-L1) = 0.0245. d CD11c-cre;Pdl1fl/fl or control mice (n = 14 Cre−, 15 Cre+) were inoculated with 5 × 105 MC38 cells. Viability of DCs was analyzed by flow cytometry on day 14. *p = 0.0322. e DCs purified from conditional knockout mice or B16 cells were treated with IFN-γ for 96 h. Cell viability was determined by MTT assay (n = 3 cells). **p(Cre-) = 0.0048; *p = 0.0101; **p(B16) = 0.0012. f DCs isolated from spleens of CD11c-cre;Pdl1fl/fl or control mice were loaded with OT-1 peptide and incubated with activated OT-1 T cells at an E:T ratio of 3 for 4 h. Cell death of cDC1 and cDC2 cells were measured by flow cytometry (n = 6 -T cells, 3 + T cells). **p = 0.0067; ***p(-T) < 0.0001; ***p(+T) < 0.0001. Data are shown as mean + SEM (a and b) or mean ± SEM (c–f) and are representative of two independent experiments (a, b, c, e, and f) or pool of four independent experiments d. n.s., not significant; *p < 0.05; **p < 0.01; ***p < 0.001 determined by two-way ANOVA in (a and b) or by unpaired two-tailed Student’s t test in (c–f). Source data are provided as a Source Data file.
Fig. 5 PD-L1 blockade reactivates T cells in tumor microenvironment for tumor control. a, b C57BL/6 mice (n = 6, except day 14 FTY720 + anti-PD-L1 n = 5) were inoculated with 2.5 × 105 MC38-OVA cells and treated with (a) 200 μg IgG or anti-PD-L1 on days 8 and 12, or (b) 250 μg IgG or anti-PD-L1 on days 14 and 18. Mice were also treated with control or FTY720 the same day as antibody treatment. Tumor growth curves were shown. ***p(8: IgG vs anti-PD-L1) < 0.0001; ***p(8: anti-PD-L1 vs FTY720+anti-PD-L1) < 0.0001; ***p(14: IgG vs anti-PD-L1) < 0.0001. c Mice (n = 4, except day 14 FTY720 + anti-PD-L1 n = 3) were treated as in 5a and 5b. IFN-γ+ CD8 T cells in tumor tissues were measured by flow cytometry on day 13 (for day 8 treatment group) or on day 19 (for day 14 treatment group). *p(8: IgG vs anti-PD-L1) = 0.0462; *p(14: IgG vs anti-PD-L1) = 0.0443; *p(14: FTY720+IgG vs FTY720+anti-PD-L1) = 0.0119; *p(8: anti-PD-L1 vs FTY720+anti-PD-L1) = 0.0245. d CD11c-cre;Pdl1fl/fl or control mice (n = 14 Cre−, 15 Cre+) were inoculated with 5 × 105 MC38 cells. Viability of DCs was analyzed by flow cytometry on day 14. *p = 0.0322. e DCs purified from conditional knockout mice or B16 cells were treated with IFN-γ for 96 h. Cell viability was determined by MTT assay (n = 3 cells). **p(Cre-) = 0.0048; *p = 0.0101; **p(B16) = 0.0012. f DCs isolated from spleens of CD11c-cre;Pdl1fl/fl or control mice were loaded with OT-1 peptide and incubated with activated OT-1 T cells at an E:T ratio of 3 for 4 h. Cell death of cDC1 and cDC2 cells were measured by flow cytometry (n = 6 -T cells, 3 + T cells). **p = 0.0067; ***p(-T) < 0.0001; ***p(+T) < 0.0001. Data are shown as mean + SEM (a and b) or mean ± SEM (c–f) and are representative of two independent experiments (a, b, c, e, and f) or pool of four independent experiments d. n.s., not significant; *p < 0.05; **p < 0.01; ***p < 0.001 determined by two-way ANOVA in (a and b) or by unpaired two-tailed Student’s t test in (c–f). Source data are provided as a Source Data file.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Cited by

See all 553

Metadata

Authors
Peng, Q., Qiu, X., Zhang, Z., Zhang, S., Zhang, Y., Liang, Y., Guo, J., Peng, H., Chen, M., Fu, Y.-X., & Tang, H.
Affiliations
  • The University of Texas Southwestern Medical Center (US)
  • Tsinghua University (CN)
  • Chinese Academy of Sciences (CN)
Corresponding author
Tang, Haidong
Venue
Nature Communications
Published
2020-09-24
Volume
11
Issue
1
Pages
4835-4835
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3089064012
Cited by
553
References
54
Citations by year
2026: 68 · 2025: 90 · 2024: 127 · 2023: 98 · 2022: 99 · 2021: 68 · 2020: 3
FWCI
24.20
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Tsinghua University (61020100119)
  • Peking University (61020100119)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
PD-L1, dendritic cells, immune checkpoint blockade, T cell activation, cDC1, interferon-gamma, antigen presentation, cross-presentation, cytotoxic T lymphocytes, tumor-infiltrating T cells, antitumor immunity, cancer immunotherapy
MeSH terms
Animals, Antigens, Neoplasm, Dendritic Cells, Disease Models, Animal, Female, Humans, Interferon-gamma, Lymphocyte Activation, Male, Mice, Inbred C57BL, T-Lymphocytes, Cytotoxic, Up-Regulation, Lymphocytes, Tumor-Infiltrating, Mice, Knockout, Cell Line, Tumor, Mice, HEK293 Cells, Tumor Microenvironment, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PD‐L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. https://app.cochat.ai/papers/10.1038/s41467-020-18570-x
The paper
Peng, Q., Qiu, X., Zhang, Z., Zhang, S., Zhang, Y., Liang, Y., Guo, J., Peng, H., Chen, M., Fu, Y.-X., & Tang, H. (2020). PD‐L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nature Communications. https://doi.org/10.1038/s41467-020-18570-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.